The PT Platform allows for the oral delivery of biologics that otherwise would break down in the digestive system through an active, naturally occurring endocytosis process.
| Program | Discovery | Pre-Clinical | Phase 1 | |
|---|---|---|---|---|
| Oral Delivery Platform | PT-1 EPO | |||
| PT-2 Octreotide | ||||
| PT-3 GLP-1 Agonist | ||||
| Key | 2021-2023 | 2023-2024 |
|---|
Through an active endocytosis process, a biologic drug fused with Imagine Pharma’s PT System is absorbed into the apical cell wall, travels and exits through the basal wall where the transporter is naturally cleaved off delivering the cargo into the blood stream.
The foundation of the three platforms forms the basis of a multi-year scientific inquiry which will lead to many discoveries and potential therapies to increase the number of patients that can benefit from our transformative first-in-class treatments. With research programs targeting areas where there are currently no treatments and current approaches are not cost effective or have failed, Imagine is pushing the boundaries of what is possible.
We are actively seeking partnerships for the development of complementary therapeutic approaches to explore a broader set of indications and reach more patients.
| R & D Engine | Discovery | Pre-Clinical | Phase 1 |
|---|---|---|---|
| 2nd Generation Oral Delivery System | |||
| Additional Oral Biologics | |||
| Comprehensive Lung Healing Initiative | |||
| Comprehensive Bowel Initiative | |||
| Personalized Blood Vessel |
|||
If there are important updates to our pipeline or research, you can be the first to hear about them.
Read the latest news, announcements, and more in the Imagine Pharma newsroom.
Our team has decades of drug discovery and development experience in the industry and are working to bring to market transformative first-in-class treatments.
Get to know the team committed to developing innovative treatments for patients.